Skip to content
Public-registry trial intelligence

Which clinical trials are running late?

A live map of 9,180 industry trials, with every readout date checked against the one first registered. Plus FDA approvals, recalls and warning letters, matched to the sponsors.

Free · refreshed nightly from ClinicalTrials.gov and the FDA (data as of 2026-11-18) · not investment or medical advice
9,180trials on the radar 380,000+trial sites mapped 46%readouts slipped 6+ months 131Phase 3 readouts in 30 days 1,114FDA warning letters matched
The finding

Almost half of trials push their readout back by more than six months.

ClinicalTrials.gov keeps every version of every record. Comparing the readout date each trial was first registered with against today's, across 5,378 active trials registered over a year ago, 46% have moved it by more than six months.

How every sponsor compares →
Share of trials slipped 6+ months, by area
Rare
56%Eye
50%Oncology
49%GI·Renal·Heme
46%Neuro
45%Respiratory
43%Infectious
41%Other
41%Immuno
40%Cardio-Met
39%

Latest activity

View the event log →
Readout date reachedPOETYK SjS-1 · Phase 3 · Immuno
Bristol-Myers Squibb $BMY
FDA approval · BLAKLYGEFA · gefurulimab
ALEXION PHARM $AZN
Trial stoppedNogapendekin alfa inbakicept (NAI) · Not yet recruiting → Withdrawn
ImmunityBio, Inc.
Readout date reachedDrugs-SNPs · Phase 2/3 · Oncology
Medicine Invention Design, Inc
FDA approval · BLAPEBRILZO · pertuzumab
BIOCON BIOLOGICS INC

Next Phase 3 readouts

Calendar →
POETYK SjS-1
Bristol-Myers Squibb $BMY · Immuno
Drugs-SNPs
Medicine Invention Design, Inc · Oncology
Pembrolizumab
Merck Sharp & Dohme LLC $MRK · Oncology
Cabergoline tablets
Changchun GeneScience Pharmaceutical Co., Ltd. · Cardio-Met
Investigational varicella vaccine
GlaxoSmithKline $GSK · Infectious

Subscribe in your calendar

What's inside

Five ways to read the pipeline

Delay Index ranking sponsors by how often their readouts slipDelay Index ranking sponsors by how often their readouts slip

Delay Index

Sponsors and stock tickers ranked by how often their readouts slip, by disease area, with the biggest moves listed. Every trial shows its originally planned date next to today's.

Open the Delay Index →
The map coloured by readout delay, with one trial's date history openThe map coloured by readout delay, with one trial's date history open

Live trial map

Every Phase 2–3 industry trial at its sites, by phase and area, or coloured by delay. Filter GLP-1, ADCs, Alzheimer's or Big Pharma, or search any drug, sponsor or $ticker.

Open the map →
FDA watch: warning letters matched to trial sponsorsFDA watch: warning letters matched to trial sponsors

FDA and manufacturing signals

New approvals, recalls, shortages and 1,114 warning letters to drug and biologics makers, matched to the sponsors on the map. 135 were about manufacturing (CGMP) in the last 12 months.

Open FDA watch →
Catalyst calendar with readouts per monthCatalyst calendar with readouts per month

Readout calendar

Every upcoming Phase 3 primary completion, or one company's, in Google, Outlook or Apple Calendar. It updates itself every night.

Subscribe →
The daily Radar Report pageThe daily Radar Report page

The daily Radar Report

One page each morning: readouts due in two weeks, what changed in the registry, delay leaders, FDA news and new Phase 3 trials.

Read today's report →

Most often late

Sponsors with 10+ active trials registered over a year ago

Delay leaderboard → · Full ranking on the map

About the data

Trials come from ClinicalTrials.gov (U.S. National Library of Medicine), including each record's version history. FDA approvals, recalls and shortages come from openFDA; warning letters from fda.gov. Everything is rebuilt every night, and every daily snapshot is kept.

Dates are reported by sponsors and are often estimates. A slipped date isn't necessarily bad news; a study may simply have grown. Records the sponsor has stopped maintaining are flagged and left out of the Delay Index.

For information only. Nothing here is investment or medical advice. Disclaimer

Get the Radar Report by email

A short weekly digest. Free; unsubscribe any time.

See Privacy.